Weber looks at the potential for PET in improving the efficiency of the drug development process, focusing on heat shock protein 90, a molecular chaperon involved in protein folding in cellular signaling, proliferation, invasion, and angiogenesis.
Page 735
O'Donnell highlights the possibilities of cancer cell–targeting radiopharmaceuticals and previews an article in this issue on a novel radiolabeled monoclonal antibody approach with nuclear localizing sequences.
Page 738
Van Laere and colleagues apply 18F-FDG PET to an exploration of the mechanisms behind beneficial effects observed in patients undergoing high-frequency anterior capsular stimulation for treatment of refractory obsessive–compulsive disorder.
Page 740
Newberg and colleagues measure the whole-body biokinetics and radiation dosimetry of 123I-IMPY and report on the pharmacologic safety of this novel radiopharmaceutical that selectively binds to amyloid plaques in Alzheimer's disease.
Page 748
Schöder and colleagues report on the utility and limitations of 18F-FDG PET/CT in identifying lymph node metastases in a segment of patients with oral cancer and clinically and radiographically negative neck findings.
Page 755
Beer and colleagues describe dosimetry studies with 18F-galacto-RGD, a novel PET tracer for imaging of αvβ3 expression, in a group of patients with various cancers.
Page 763
de Geus-Oei and colleagues explore the potential of 18F-FDG PET for reducing the number of unnecessary hemithyroidectomies in the preoperative assessment of thyroid nodules in patients with inconclusive fine-needle aspiration biopsy results.
Page 770
Floeth and colleagues assess the differential diagnostic value of PET using 18F-FET in patients with newly diagnosed solitary intracerebral lesions showing ring enhancement on contrast-enhanced MRI.
Page 776
Millet and colleagues describe a novel quantitative approach with SPECT to study the interaction between 123I-IMZ and benzodiazepine receptors.
Page 783
Smith-Jones and colleagues compare 68Ga-DOTA-F(ab′)2-herceptin PET and 18F-FDG PET in a mouse model in predicting tumor response to 17AAG, one of a new class of drugs currently in early clinical trials for breast cancer.
Page 793
Hoffmann and colleagues provide detailed information on performing state-of-the-art coronary CT angiography, including patient preparation, image acquisition, and evaluation techniques, and review potential clinical applications and limitations.
Page 797
Uusijärvi and colleagues investigate the suitability of several electron- and positron-emitting radiolanthanides for radionuclide therapy, with special reference to dosimetric and production possibilities.
Page 807
Frankle and colleagues define an optimal analytic method to derive accurate serotonin transporter receptor parameters with 11C-DASB PET, a technique with promise in enhancing the quality of information derived in clinical studies of depression, schizophrenia, and addictive behaviors.
Page 815
Chen and colleagues report on toxicity studies of the anti-CD33 monoclonal antibody, HuM195, modified with targeting peptides and labeled with 111In and discuss the promise of this agent in targeted radiotherapy for acute myeloid leukemia.
Page 827
Cho and colleagues describe in vitro evaluations using 3H-AMP with tumor cell lines to explore the potential of 11C-AMP for targeting the nucleoside transport pathway in PET imaging of tumors.
Page 837
Tolmachev and colleagues perform in vitro and in vivo studies to determine whether an 111In-labeled affibody molecule can be used for imaging HER2 overexpression and discuss the implications for imaging and targeted therapy of breast cancer.
Page 846
Chen and colleagues explore the feasibility of radioiodine therapy involving the targeting of hepatoma cells by tissue-specific expression of the human sodium/iodide symporter gene directed by the murine albumin enhancer and promoter.
Page 854
Hosokawa and colleagues report on a method for identifying coronary vulnerable plaques with a catheter-based intravascular radiation detector and 18F-FDG.
Page 863
Khaw and colleagues investigate the use of bispecific antibody complexes and 99mTc-labeled negatively charged polymers for in vivo visualization of very small atherosclerotic lesions in a mouse model.
Page 868
Deng and colleagues describe the use of 131I-FIAU for assessing lung metastases in a mouse model and discuss the implications for future nuclear medicine techniques to monitor the efficacy of gene delivery and expression.
Page 877
Delbeke and colleagues present the full text of a new SNM guideline compiled to assist physicians in recommending, performing, interpreting, and reporting the results of 18F-FDG PET/CT for oncologic imaging of adult and pediatric patients.
Page 885
ON THE COVER
Images illustrating 18F-FET PET findings false positive for malignancy in a 50-y-old woman with a demyelinating lesion. MRI (top left) shows a ring-enhancing lesion; 18F-FET PET (top right) shows significant uptake, indicating neoplasia; photomicrography of a CD68-immunostained biopsy specimen (bottom left) shows an acute demyelinating lesion with massive invasion of macrophages; and immunohistochemistry for neurofilaments (bottom right) shows persisting axonal processes but also axonal damage within the lesion.
SEE PAGE 780